Clinical Trial

ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）

Name: ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE） — clinical trial record (NCT07314567)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Relapsed/Refractory Systemic lupus erythematosus (SLE)

Trial Details

NCT Number	NCT07314567
Lead Sponsor	Tongji Hospital
Conditions	System Lupus Erythematosus(SLE)
Enrollment	22 participants
Start Date	2026-01-01
Primary Completion	2027-10-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-02